Journal of Cannabis Research,
Journal Year:
2023,
Volume and Issue:
5(1)
Published: June 13, 2023
Abstract
The
use
of
cannabidiol
(CBD)
for
therapeutic
purposes
is
receiving
considerable
attention,
with
speculation
that
CBD
can
be
useful
in
a
wide
range
conditions.
Only
one
product,
purified
form
plant-derived
solution
(Epidiolex),
approved
the
treatment
seizures
patients
Lennox-Gastaut
syndrome,
Dravet
or
tuberous
sclerosis
complex.
Appraisal
evidence
base
complicated
by
fact
products
sometimes
have
additional
phytochemicals
(like
tetrahydrocannabinol
(THC))
present,
which
make
identification
active
pharmaceutical
ingredient
(API)
positive
studies
difficult.
aim
present
review
to
critically
clinical
using
only,
order
establish
upcoming
indications
might
beneficial.
areas
there
most
support
are
anxiety
(positive
data
7
uncontrolled
and
17
randomised
controlled
trials
(RCTs)),
psychosis
schizophrenia
1
study
8
RCTs),
PTSD
2
4
RCTs)
substance
abuse
3
RCTs).
Seven
improve
sleep
quality,
but
this
has
only
been
verified
small
RCT.
Limited
supports
Parkinson’s
(3
autism
smoking
cessation
(2
graft-versus-host
disease
intestinal
permeability
(1
RCT
each).
Current
does
not
oral
pain
(at
least
as
an
acute
analgesic)
COVID
symptoms,
cancer,
Huntington’s
type
diabetes.
In
conclusion,
published
multiple
beyond
epilepsy.
However,
limited
number
investigating
effects
CBD,
testing
healthy
volunteers,
very
patient
numbers.
Large
confirmatory
phase
required
all
indications.
Australian & New Zealand Journal of Psychiatry,
Journal Year:
2020,
Volume and Issue:
55(1), P. 7 - 117
Published: Dec. 22, 2020
Objectives:
To
provide
advice
and
guidance
regarding
the
management
of
mood
disorders,
derived
from
scientific
evidence
supplemented
by
expert
clinical
consensus
to
formulate
s
that
maximise
utility.
Methods:
Articles
information
sourced
search
engines
including
PubMed,
EMBASE,
MEDLINE,
PsycINFO
Google
Scholar
were
literature
known
disorders
committee
(e.g.
books,
book
chapters
government
reports)
published
depression
bipolar
disorder
guidelines.
Relevant
was
appraised
discussed
in
detail
members
committee,
with
a
view
formulating
developing
consensus-based
recommendations
guidance.
The
guidelines
subjected
rigorous
consultation
external
review
involving:
advisors,
key
stakeholders,
professional
bodies
specialist
groups
interest
disorders.
Results:
Royal
Australian
New
Zealand
College
Psychiatrists
practice
2020
(MDcpg
)
up-to-date
is
informed
experience.
guideline
intended
for
use
psychiatrists,
psychologists,
primary
care
physicians
others
an
mental
health
care.
Conclusion:
MDcpg
builds
on
previous
2015
maintains
its
joint
focus
both
depressive
It
provides
within
evidence-based
framework,
consensus.
Mood
committee:
Gin
S
Malhi
(Chair),
Erica
Bell,
Darryl
Bassett,
Philip
Boyce,
Richard
Bryant,
Hazell,
Malcolm
Hopwood,
Bill
Lyndon,
Roger
Mulder,
Porter,
Ajeet
B
Singh
Greg
Murray.
Biomolecules,
Journal Year:
2020,
Volume and Issue:
10(11), P. 1575 - 1575
Published: Nov. 19, 2020
The
potential
therapeutic
use
of
some
Cannabis
sativa
plant
compounds
has
been
attracting
great
interest,
especially
for
managing
neuropsychiatric
disorders
due
to
the
relative
lack
efficacy
current
treatments.
Numerous
studies
have
carried
out
using
main
phytocannabinoids,
tetrahydrocannabinol
(THC)
and
cannabidiol
(CBD).
CBD
displays
an
interesting
pharmacological
profile
without
becoming
a
drug
abuse,
unlike
THC.
In
this
review,
we
focused
on
anxiolytic,
antidepressant,
antipsychotic
effects
found
in
animal
human
studies.
rodents,
results
suggest
that
depend
dose,
strain,
administration
time
course
(acute
vs.
chronic),
route
administration.
addition,
certain
key
targets
related
with
these
actions,
including
cannabinoid
receptors
(CB1r
CB2r),
5-HT1A
receptor
neurogenesis
factors.
Preliminary
clinical
trials
also
support
as
antipsychotic,
more
importantly,
positive
risk-benefit
profile.
These
promising
development
large-scale
further
evaluate
new
treatment
psychiatric
disorders.
Cannabis and Cannabinoid Research,
Journal Year:
2020,
Volume and Issue:
6(1), P. 19 - 27
Published: April 9, 2020
The
term
"hemp"
refers
to
Cannabis
sativa
cultivars
grown
for
industrial
purposes
that
are
characterized
by
lower
levels
of
tetrahydrocannabinol
(THC),
the
active
principle
responsible
psychotropic
effects.
Hemp
is
an
extraordinary
crop,
with
enormous
social
and
economic
value,
since
it
can
be
used
produce
food,
textiles,
clothing,
biodegradable
plastics,
paper,
paint,
biofuel,
animal
feed,
as
well
lighting
oil.
Various
parts
hemp
plant
represent
a
valuable
source
food
ingredients
nutritional
supplements.
While
inflorescence
rich
in
nonpsychoactive,
yet
biologically
cannabinoids,
such
cannabidiol
(CBD),
which
exerts
potent
anxiolytic,
spasmolytic,
anticonvulsant
effects,
hempseed
has
pleasant
nutty
taste
represents
essential
amino
acids
fatty
acids,
minerals,
vitamins,
fibers.
In
addition,
oil
healthy
polyunsaturated
sprouts
antioxidants.
This
review
article
aims
provide
comprehensive
outlook
from
multidisciplinary
perspective
on
scientific
evidence
supporting
beneficial
properties
when
consumed
or
supplement.
Marketing
hemp-derived
products
subjected
diversified
complex
regulations
worldwide
several
reasons,
including
fact
CBD
also
principal
pharmaceutical
agents
regulatory
bodies
some
cases
ban
regardless
its
THC
content.
Some
key
aspects
scenario
analyzed
discussed
this
article.
Pharmacology,
Journal Year:
2022,
Volume and Issue:
107(3-4), P. 131 - 149
Published: Jan. 1, 2022
<b><i>Background:</i></b>
There
is
a
growing
interest
in
the
use
of
cannabis
(and
its
extracts),
as
well
CBD
oil
(hemp
extracts
containing
cannabidiol),
for
therapeutic
purposes.
While
there
reason
to
believe
that
cannabinoids
may
be
efficacious
number
different
diseases
and
syndromes,
exist
limited
objective
data
supporting
crude
materials
(CBD
oil,
extracts,
and/or
itself).
<b><i>Summary:</i></b>
In
present
review,
we
examined
pure
cannabinoid
compounds
(dronabinol,
nabilone,
CBD),
partially
purified
medicinal
(nabiximols),
provide
guidance
on
potential
uses
high-THC
oil.
general,
support
role
cannabis/cannabinoids
pain,
seizure
disorders,
appetite
stimulation,
muscle
spasticity,
treatment
nausea/vomiting.
Given
biological
activities
cannabinoids,
utility
central
nervous
system
disorders
(such
neurodegenerative
diseases,
PTSD,
addiction)
or
cancer.
However,
those
are
much
less
compelling.
<b><i>Key
Message:</i></b>
On
balance,
reasons
medical
extract
(Δ<sup>9</sup>-THC-dominant
CBD-dominant),
but
more
careful
research
required.
Postgraduate Medicine,
Journal Year:
2019,
Volume and Issue:
132(1), P. 56 - 61
Published: Nov. 12, 2019
Context:
Chronic
pain
is
highly
prevalent
in
most
of
the
industrialized
nations
around
world.
Despite
documented
adverse
effects,
opioids
are
widely
used
for
management.
Cannabinoids,
and
specifically
Cannabidiol,
proposed
as
an
opioid
alternative,
having
comparable
efficacy
with
better
safety
profile.Objectives:
We
aim
to
investigate
impact
full
hemp
extract
cannabidiol
(CBD)
on
use
quality
life
indicators
among
chronic
patients.Methods:
An
initial
sample
131
patients
was
recruited
from
a
private
management
center's
investigative
population.
Ninety-seven
completed
8-week
study.
The
primary
inclusion
criteria
included
between
30
65
years
old
who
have
been
at
least
1
year.
Data
were
collected
three
different
time
points:
baseline,
4,
8
weeks.
Opioid
other
medication
evaluated
via
psychiatric
treatment
receipt.
Improvement
using
four
indices:
Pain
Disability
Index
(PDI-4);
Pittsburgh
Sleep
Quality
(PSQI),
Intensity
Interference
(PEG);
Patient
Health
Questionnaire
(PHQ-4).Results:
Over
half
(53%)
reduced
or
eliminated
their
within
weeks
after
adding
CBD-rich
regimens.
Almost
all
CBD
users
(94%)
reported
improvements.
results
indicated
significant
relationship
PSQI
(p
=
0.003),
PEG
0.006).
There
trend
toward
improvement
but
no
PHQ
PDI.Conclusion:
could
significantly
reduce
improve
sleep
currently
management.Key
Message:
This
prospective,
single-arm
cohort
study
potential
role
cannabinoids
alternative
opioids.
indicate
that
enabled
our
eliminate
indices.
Journal of Cannabis Research,
Journal Year:
2021,
Volume and Issue:
3(1)
Published: Feb. 18, 2021
Abstract
Background
Public
and
medical
interest
in
cannabidiol
(CBD)
has
been
rising,
CBD
is
now
available
from
various
sources.
Research
into
the
effects
of
low-dose
on
outcomes
like
stress,
anxiety,
sleep
problems
have
scarce,
so
we
conducted
an
online
survey
users
to
better
understand
patterns
use,
dose,
self-perceived
CBD.
Methods
The
sample
consisted
387
current
or
past-CBD
who
answered
a
20-question
survey.
was
sent
out
through
email
databases
social
media.
Participants
reported
basic
demographics,
use
patterns,
reasons
for
sleep,
stress.
Results
(
N
=
387)
61.2%
females,
mostly
between
25
54
years
old
(72.2%)
primarily
based
UK
(77.4%).
top
4
using
were
anxiety
(42.6%),
(42.5%),
stress
(37%),
general
health
wellbeing
(37%).
Fifty-four
per
cent
less
than
50
mg
daily,
72.6%
used
sublingually.
Adjusted
logistic
models
show
females
had
lower
odds
males
[OR
0.45,
95%
CI
0.30–0.72]
post-workout
muscle-soreness
0.46,
95%CI
0.24–0.91]
but
higher
1.60,
0.02–2.49]
insomnia
1.87,
1.13–3.11].
Older
individuals
wellbeing,
sore
muscles,
skin
conditions,
focusing,
pain.
Respondents
that
effective
problems,
those
drug
conditions.
Conclusion
This
indicated
take
manage
other
symptoms,
often
low
doses,
these
vary
by
demographic
characteristics.
Further
research
required
how
representative
user,
might
impact
mental
symptoms
problems.
PLoS ONE,
Journal Year:
2020,
Volume and Issue:
15(3), P. e0230167 - e0230167
Published: March 26, 2020
Cannabis
related
online
searches
are
associated
with
positive
attitudes
toward
medical
cannabis,
particularly
when
information
is
obtained
from
dispensaries.
Since
pain
the
main
reason
for
medicinal
cannabis
use,
dispensary
websites
has
potential
to
shape
attitude
of
patients
towards
cannabis.
This
relevant
because
demonstrated
efficacy
in
neuropathic
low
tetrahydrocannabinol
(THC)
concentrations
(<
5–10%),
contrast
potent
(>15%
THC),
which
highly
rewarded
recreational
realm.
The
role
CBD
not
clear,
however
it
gained
popularity.
Thus,
we
hypothesize
that
potency
advertised
similar
purposes,
would
potentially
create
a
misconception
current
lack
knowledge
surrounding
potencies
legal
market
limits
ability
generate
clear
policies
regarding
advertising
protect
willing
use
their
condition.
evaluated
THC
and
content
products
offered
dispensaries
United
States
determine
products'
suitability
compare
strength
programs.
We
recorded
all
herb
provided
by
compared
them
between
or
within
states.
Four
Western
states
(CA,
CO,
NM,
WA)
five
Northeastern
(ME,
MA,
NH,
RI,
VT)
were
included.
A
total
8,505
across
653
sampled.
Despite
differences
uses
average
concentration
programs
was
(19.2%
±6.2)
(21.5%
±6.0)
different
programs,
same
(CO
WA).
Lower
accompanied
higher
products.
majority
products,
regardless
have
>15%
(70.3%
-
91.4%
products).
These
stated
seem
unsuitable
chronic
pain.
Therefore,
this
could
induce
high
safe
treat
data
consistent
reports
nationwide
illegal
actually
measured,
indicates
consuming
these
may
be
at
risk
acute
intoxication
long-term
side
effects.
Our
study
offers
grounds
develop
help
prevent
misconceptions
reduce
risks
patients.
